vs
安捷伦科技（A）与LG化学（CHE）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是LG化学的4.3倍（$1.8B vs $420.0M）。安捷伦科技净利率更高（17.0% vs 15.8%，领先1.2%）。安捷伦科技同比增速更快（7.0% vs 3.1%）。过去两年安捷伦科技的营收复合增速更高（6.9% vs 5.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
LG化学是韩国最大的化工企业，总部位于韩国首尔，2021年按销售额统计为全球第九大化工企业。其前身为生产化妆品的乐喜化学工业株式会社，目前已全面转型为仅面向企业客户的B2B经营模式。
A vs CHE — 直观对比
营收规模更大
A
是对方的4.3倍
$420.0M
营收增速更快
A
高出3.9%
3.1%
净利率更高
A
高出1.2%
15.8%
两年增速更快
A
近两年复合增速
5.9%
损益表 — Q1 2026 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $420.0M |
| 净利润 | $305.0M | $66.3M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 20.1% |
| 净利率 | 17.0% | 15.8% |
| 营收同比 | 7.0% | 3.1% |
| 净利润同比 | -4.1% | -7.6% |
| 每股收益（稀释后） | $1.07 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACHE
| Q1 26 | $1.8B | $420.0M | ||
| Q4 25 | $1.9B | $639.3M | ||
| Q3 25 | $1.7B | $624.9M | ||
| Q2 25 | $1.7B | $618.8M | ||
| Q1 25 | $1.7B | $646.9M | ||
| Q4 24 | $1.7B | $411.0M | ||
| Q3 24 | $1.6B | $391.4M | ||
| Q2 24 | $1.6B | $374.6M |
净利润ACHE
| Q1 26 | $305.0M | $66.3M | ||
| Q4 25 | $434.0M | $76.8M | ||
| Q3 25 | $336.0M | $64.2M | ||
| Q2 25 | $215.0M | $52.5M | ||
| Q1 25 | $318.0M | $71.8M | ||
| Q4 24 | $351.0M | $90.3M | ||
| Q3 24 | $282.0M | $75.8M | ||
| Q2 24 | $308.0M | $70.9M |
毛利率ACHE
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 35.2% | ||
| Q3 25 | 51.1% | 31.5% | ||
| Q2 25 | 51.9% | 29.8% | ||
| Q1 25 | 53.5% | 33.5% | ||
| Q4 24 | 53.9% | 1.2% | ||
| Q3 24 | 54.2% | -1.2% | ||
| Q2 24 | 54.4% | -4.1% |
营业利润率ACHE
| Q1 26 | 19.6% | 20.1% | ||
| Q4 25 | 23.8% | 15.7% | ||
| Q3 25 | 20.7% | 12.0% | ||
| Q2 25 | 18.0% | 11.0% | ||
| Q1 25 | 22.4% | 14.6% | ||
| Q4 24 | 24.0% | 27.7% | ||
| Q3 24 | 21.1% | 23.5% | ||
| Q2 24 | 23.1% | 23.5% |
净利率ACHE
| Q1 26 | 17.0% | 15.8% | ||
| Q4 25 | 23.3% | 12.0% | ||
| Q3 25 | 19.3% | 10.3% | ||
| Q2 25 | 12.9% | 8.5% | ||
| Q1 25 | 18.9% | 11.1% | ||
| Q4 24 | 20.6% | 22.0% | ||
| Q3 24 | 17.9% | 19.4% | ||
| Q2 24 | 19.6% | 18.9% |
每股收益（稀释后）ACHE
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $5.45 | ||
| Q3 25 | $1.18 | $4.46 | ||
| Q2 25 | $0.75 | $3.57 | ||
| Q1 25 | $1.11 | $4.86 | ||
| Q4 24 | $1.23 | $6.00 | ||
| Q3 24 | $0.97 | $5.00 | ||
| Q2 24 | $1.05 | $4.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $16.9M |
| 总债务越低越好 | $3.0B | $91.2M |
| 股东权益账面价值 | $6.9B | $848.0M |
| 总资产 | $12.8B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资ACHE
| Q1 26 | $1.8B | $16.9M | ||
| Q4 25 | $1.8B | $74.5M | ||
| Q3 25 | $1.5B | $129.8M | ||
| Q2 25 | $1.5B | $249.9M | ||
| Q1 25 | $1.5B | $173.9M | ||
| Q4 24 | $1.3B | $178.3M | ||
| Q3 24 | $1.8B | $238.5M | ||
| Q2 24 | $1.7B | $222.9M |
总债务ACHE
| Q1 26 | $3.0B | $91.2M | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益ACHE
| Q1 26 | $6.9B | $848.0M | ||
| Q4 25 | $6.7B | $979.4M | ||
| Q3 25 | $6.4B | $1.1B | ||
| Q2 25 | $6.1B | $1.2B | ||
| Q1 25 | $6.0B | $1.2B | ||
| Q4 24 | $5.9B | $1.1B | ||
| Q3 24 | $5.9B | $1.2B | ||
| Q2 24 | $6.2B | $1.2B |
总资产ACHE
| Q1 26 | $12.8B | $1.5B | ||
| Q4 25 | $12.7B | $1.5B | ||
| Q3 25 | $12.2B | $1.6B | ||
| Q2 25 | $12.2B | $1.7B | ||
| Q1 25 | $11.9B | $1.7B | ||
| Q4 24 | $11.8B | $1.7B | ||
| Q3 24 | $11.0B | $1.8B | ||
| Q2 24 | $10.9B | $1.7B |
负债/权益比ACHE
| Q1 26 | 0.44× | 0.11× | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $88.2M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.88× | 1.33× |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流ACHE
| Q1 26 | $268.0M | $88.2M | ||
| Q4 25 | $545.0M | $133.5M | ||
| Q3 25 | $362.0M | $83.4M | ||
| Q2 25 | $221.0M | $138.6M | ||
| Q1 25 | $431.0M | $32.7M | ||
| Q4 24 | $481.0M | $164.9M | ||
| Q3 24 | $452.0M | $90.5M | ||
| Q2 24 | $333.0M | $77.5M |
自由现金流ACHE
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $117.2M | ||
| Q3 25 | $259.0M | $66.0M | ||
| Q2 25 | $107.0M | $122.8M | ||
| Q1 25 | $334.0M | $19.5M | ||
| Q4 24 | $388.0M | $152.2M | ||
| Q3 24 | $360.0M | $77.0M | ||
| Q2 24 | $230.0M | $66.5M |
自由现金流率ACHE
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 18.3% | ||
| Q3 25 | 14.9% | 10.6% | ||
| Q2 25 | 6.4% | 19.8% | ||
| Q1 25 | 19.9% | 3.0% | ||
| Q4 24 | 22.8% | 37.0% | ||
| Q3 24 | 22.8% | 19.7% | ||
| Q2 24 | 14.6% | 17.7% |
资本支出强度ACHE
| Q1 26 | 5.2% | 4.1% | ||
| Q4 25 | 5.0% | 2.6% | ||
| Q3 25 | 5.9% | 2.8% | ||
| Q2 25 | 6.8% | 2.6% | ||
| Q1 25 | 5.8% | 2.1% | ||
| Q4 24 | 5.5% | 3.1% | ||
| Q3 24 | 5.8% | 3.5% | ||
| Q2 24 | 6.5% | 3.0% |
现金转化率ACHE
| Q1 26 | 0.88× | 1.33× | ||
| Q4 25 | 1.26× | 1.74× | ||
| Q3 25 | 1.08× | 1.30× | ||
| Q2 25 | 1.03× | 2.64× | ||
| Q1 25 | 1.36× | 0.46× | ||
| Q4 24 | 1.37× | 1.83× | ||
| Q3 24 | 1.60× | 1.19× | ||
| Q2 24 | 1.08× | 1.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
CHE
| Homecare | $371.1M | 88% |
| Inpatient | $35.9M | 9% |
| Other | $13.0M | 3% |
